Healing Innovators

Having seen numerous attempts to tackle the escalating anti-microbial resistance global crisis Inthelia believes that the solution is not more anti-microbials but a complete paradigm shift towards a new type of drug therapy that works along side existing treatments.

Host-targeted therapy (HTT) for treating infections focuses on modulating host factors or pathways that pathogens exploit to cause disease, rather than targeting the pathogens directly.

By targeting host molecules, pathways, or immune responses, HTT aims to enhance the host’s ability to control or eliminate the infection, while potentially reducing the risk of resistance development by the pathogen.